Prof Maria-Victoria Mateos (University Hospital of Salamanca, Salamanca, Spain) talks to Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, USA) discuss key advances in the treatment of smoldering multiple myeloma for ecancer at the 16th International Myeloma Workshop in New Delhi, India.
With the standard of care for smoldering multiple myeloma (SMM) being observation, a number of trials have assessed the early treatment of selected SMM patients to identify whether alternative treatment options should be explored.
Prof Mateos first discusses the QuiRedex trial that selected patients at high risk for progression. In these patients, early treatment with lenalidomide plus dexamethasone compared to observation provided a significant benefit both in terms of time to progression to active disease and overall survival.
Further studies are discussed that if positive would support the use of early treatment for patients with high-risk SMM.
Summarising the discussion, it was suggested that based on current evidence ultra-high risk SMM patients should be treated and “strive for cure”.
With the potential for novel biological and genomic markers to more accurately predict the risk of progression, it is clear the therapeutic landscape for both high risk and ultra-high risk SMM patients is set to evolve.
This discussion is continued here, where the experts cover the treatment of multiple myeloma patients in the relapsed setting.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceuticals (A Johnson & Johnson Company).